|
|
Profile
|
Delegates :
Vicotor Stone (Yoshihide Ishii) |
|
Incorporated :
November 28 , 2024 |
Paid in Capital :
Million yen |
Employees :
10 人 |
Address :
Muraokahigashi 2-26-1 Shonan Health Innovation Park, Fujisawa-si KANAGAWA
〒251-0012
|
TEL/FAX :
+81-50-5799-8507 / |
URL：
https://alloytx.com/alloy-jp/ |
Attachment :
 AlloyTx_Brochure_marged_JP.pdf [ 1.7MiB ] |
Mission/Background :
Alloy Therapeutics Co., Ltd is the Japanese subsidiary of Alloy Therapeutics, Inc., headquartered in Boston, USA, established in 2024. Located in Shonan Health Innovation Park, Kanagawa, the company provides drug discovery support platforms covering modalities such as antibodies, cell therapies, and genetic medicines.
Leveraging these advanced technologies, we collaborate on drug discovery with diverse partners—from academia to pharmaceutical companies—through licensing, contract research (CRO), and venture creation.
In addition, we strive to build a global drug discovery ecosystem by addressing the diverse challenges in Japan's ecosystem. This includes introducing advanced technologies from abroad, promoting regional revitalization, fostering talent, supporting the global expansion of startups, and translating academic research into real-world applications.
|
|
Technology & Business
|
Alloy Therapeutics Co., Ltd. offers platforms for next-generation humanized antibody mouse technology and iPS cell-derived CAR-T therapies. It focuses on developing off-the-shelf cell therapies to reduce costs and improve accessibility. With a venture studio function, Alloy supports biotech startups and reinvests 100% of its revenue into innovation, aiming to expand access to advanced drug discovery technologies worldwide.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Next-Generation Humanized Antibody Mouse Technology
|
Service/Marketing
|
An advanced platform for accelerating antibody drug discovery, supporting monoclonal and bispecific antibody development.
|
|
TCR Mimic (TCRm) Antibody Technology
|
Service/Marketing
|
Enables development of antibodies targeting intracellular antigens, offering new therapeutic options for cancer.
|
|
iPS Cell-Derived CAR-T / CAR-NK Platforms (iCAR-T, iCAR-NK)
|
Service/Marketing
|
Next-generation immune cell therapy platforms designed for off-the-shelf treatments.
|
|
Anticlastic (TM) Antisense Technology
|
Service/Marketing
|
A platform supporting innovative antisense oligonucleotide (ASO) drug development in the genetic medicine field.
|
|
Venture Studio Services
|
Service/Marketing
|
Provides support for biotech startup creation, fundraising, and operations, fostering an ecosystem for drug discovery.
|
|
|
|